paroxetine
Trade name: paxil
Approved
Dec 29, 1992
Paroxetine, also known by the trade names Paxil and Seroxat. PAXIL (paroxetine hydrochloride) is an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate. It is used to treat major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder and premenstrual dysphoric disorder. Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown. Paroxetine, a phenylpiperidine derivative, was originally developed in 1975 by Jorgen Buus-Lassen and associates working in a small Danish company Ferrosan. Paroxetine was the second SSRI synthesized by Buus-Lassen In 1975. — NCATS
Clinical trial activity
240 trials · 222 clinical orgs · 30 marketing orgs
Earliest trial started Sep 1, 1996 (NCT00018733)
Timeline
1990s
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- Jul 3, 2003
Sebela Pharmaceuticals — NDA Secondary Org
- Jul 30, 2003
Apotex — Marketing Organization
- Mar 8, 2004
Mylan — Marketing Organization
- Mar 8, 2004
Upsher-Smith Laboratories — Marketing Organization
- Mar 8, 2004
PHARMOBEDIENT — Marketing Organization
- Aug 15, 2005
Chartwell Pharmaceuticals — Marketing Organization
- Mar 7, 2007
Zydus Discovery DMCC — Marketing Organization
- Jun 29, 2007
Roxane Laboratories — Marketing Organization
- Jun 29, 2007
Sun Pharmaceuticals — Marketing Organization
- Jun 29, 2007
Teva — Marketing Organization
- Jun 29, 2007
Boehringer Ingelheim — Marketing Organization
- Jul 25, 2007
Aurobindo Pharma — Marketing Organization
2010s
- Jun 21, 2010
Oxford Pharmaceuticals — Marketing Organization
- Jun 28, 2013
LEGACY PHARMA — Marketing Organization
- Oct 31, 2014
Prinston Inc — Marketing Organization
- Nov 27, 2015
Jubilant Innovation Ltd. — Marketing Organization
- Jun 10, 2016
Lannett Company, Inc. — Marketing Organization
- Jan 20, 2017
Lupin — Marketing Organization
- Jun 20, 2017
Actavis — Marketing Organization
- Jun 20, 2017
Allergan PLC (2015) — Marketing Organization
- Jun 12, 2018
Sciecure Pharma Inc — Marketing Organization
2020s
- Feb 16, 2021
Shijiazhuang Pharma Group (CSPC) — Marketing Organization
- Aug 11, 2021
Epic Pharma Llc — Marketing Organization
- Aug 11, 2021
Sinotherapeutics — Marketing Organization
- Aug 27, 2021
Cadila Healthcare — Marketing Organization
- Sep 3, 2021
Novitium Pharma — Marketing Organization
- Sep 3, 2021
Ani Pharmaceuticals — Marketing Organization
- Nov 2, 2021
Yiling Pharmaceutical Inc. — Marketing Organization
- Sep 24, 2025
Alembic — Marketing Organization
- Mar 5, 2026
Annora Pharma — Marketing Organization
Indications
Approved for
Studied for
- Agoraphobia · Phase 4
- Alcoholism · Phase 4
- Anovulation · Phase 1
- Antidepressive Agents · Early Phase 1
- Anxiety · Phase 4
- Anxiety Disorders · Phase 4
- Arthritis, Rheumatoid · Phase 3
- Bipolar Disorder · Phase 4
- Burning Mouth Syndrome · Phase 3
- Combat Disorders · Phase 4
- Coronary Artery Disease · Phase 4
- Cytochrome P-450 CYP2D6 · Phase 1
- Cytochrome P-450 CYP3A · Phase 1
- Dementia · Phase 4
- Deprescriptions · Early Phase 1
- Depression · Phase 4
- Diabetes Mellitus, Type 2 · Phase 3
- Diabetic Neuropathies · Phase 1
- Drug Interactions · Phase 1
- Dysthymic Disorder · Phase 4
- Endothelial Cells · Phase 4
- Fibromyalgia · Phase 4
- Healthy Volunteers · Phase 4
- Heart Disease Risk Factors · Phase 4
- Heart Diseases · Phase 2
- Hepatitis C, Chronic · Phase 3
- HIV Infections · Phase 1/Phase 2
- Hot Flashes · Phase 3
- Hypercapnia · Phase 1
- Hypertension · Phase 4
- Idiopathic Pulmonary Fibrosis · Phase 1
- Irritable Bowel Syndrome · Phase 4
- Major Depressive Disorder · Phase 4
- Menopause · Phase 4
- Mental Disorders · Phase 4
- Metabolic Detoxication, Phase I · Phase 1
- Multiple Sclerosis · Phase 3
- Myocardial Infarction · Phase 2
- Neoplasms · Phase 1/Phase 2
- Neuralgia · Phase 3
- Obsessive Behavior · Phase 4
- Obsessive-Compulsive Disorder · Phase 4
- Pain · Phase 4
- Parkinson Disease · Phase 3
- Phobia, Social · Phase 4
- Phobic Disorders · Phase 4
- Postmenopause · Phase 4
- Premature Ejaculation · Phase 3
- Premenstrual Dysphoric Disorder · Phase 4
- Premenstrual Syndrome · Phase 4
- Prostatic Hyperplasia · Phase 1
- Prostatic Neoplasms · Phase 2/Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Psychophysiologic Disorders · Phase 3
- Respiratory Insufficiency · Phase 1
- Schizophrenia · Phase 3
- Sepsis · Phase 2
- Shock, Septic · Phase 2
- Sleep Apnea, Obstructive · Phase 4
- Sleep Initiation and Maintenance Disorders · Phase 4
- Stress Disorders, Post-Traumatic · Phase 4
- Suicidal Ideation · Phase 4
- Tinnitus · Phase 4
- Vasomotor System · Phase 3
Mechanism of action
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
reuptake inhibitor
Approval history
- approvedDec 29, 1992
Chemistry & pharmacology
SMILES
FC1=CC=C(C=C1)[C@@H]2CCNC[C@H]2COC3=CC4=C(OCO4)C=C3- Mol. weight
- 329.3654 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaParoxetine ↗
- NCATS41VRH5220H ↗
- ChEMBLCHEMBL4297919 ↗
- ChEMBLCHEMBL1708 ↗
- ChEMBLCHEMBL6067650 ↗
- ChEMBLCHEMBL1200609 ↗
- ChEMBLCHEMBL1256912 ↗
- ChEMBLCHEMBL490 ↗
Also known as
- (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
- (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
- (3s-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
- (3s-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
- brisdelle
- brl-29060
- brl-29060
- brl 29060a
- brl 29060a
- brl 29060a
- brl 29060a
- brl 29060a
- brl 29060a
- brl-29060a
- paroxetina
- paroxetina
- paroxetine
- paroxetine
- paroxetine
- paroxetine
- paroxetine
- paroxetine
- paroxetine
- paroxetine
- paroxetine hcl
- paroxetine hcl
- paroxetine hcl
- paroxetine hydrochloride
- paroxetine hydrochloride
- paroxetine hydrochloride
- paroxetine hydrochloride
- paroxetine hydrochloride anhydrous
- paroxetine hydrochloride hemihydrate
- paroxetine hydrochloride hemihydrate
- paroxetine hydrochloride hydrate
- paroxetine mesilate
- paroxetine mesylate
- paroxetine mesylate
- paroxetine mesylate
- paroxetine mesylate
- paroxetine mesylate
- paroxetinum
- paroxetinum
- paxetil
- paxil
- paxil
- paxil
- paxil
- paxil
- paxil [as hydrochloride]
- paxil cr
- paxil cr
- pexeva
- pexeva
- pot.mes
- pot.mes
- seroxat
- seroxat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07070232 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2025 | Biontech |
| NCT07057011 | N/A | Jul 1, 2025 | South Valley University |
| NCT06957210 | N/A | May 6, 2025 | CMH Nowshera, Pakistan Army |
| NCT06957223 | N/A | May 6, 2025 | CMH Nowshera, Pakistan Army |
| NCT06796946 | Early Phase 1 (Phase 1) | Apr 30, 2025 | University of Huelva |
| NCT07025590 | N/A | Apr 22, 2025 | Shantou University |
| NCT06799169 | Phase 4 | Mar 31, 2025 | University of California, Irvine |
| NCT06763484 | Phase 2 | Jan 1, 2025 | Universidad Nacional Autonoma de Honduras |
| NCT06232109 | Phase 1 | Feb 22, 2024 | Asceneuron S.A., QPS |
| NCT06203275 | Phase 3 | Jan 31, 2024 | Tanta University |
| NCT06231745 | Phase 3 | Jan 31, 2024 | Tanta University |
| NCT06065735 | Phase 1 | Sep 29, 2023 | GlaxoSmithKline |
| NCT05992428 | Phase 1 | Aug 22, 2023 | Dong-A Pharmaceutical |
| NCT05725837 | Phase 2 | Jun 10, 2023 | Universidade do Extremo Sul Catarinens |
| NCT06358014 | N/A | May 12, 2023 | Capital Medical University |
| NCT06025474 | Phase 3 | Jan 1, 2023 | University of Naples Frederico II |
| NCT05637671 | Phase 3 | Dec 31, 2022 | Cairo University |
| NCT05175430 | Phase 1 | Oct 24, 2022 | University of Basel |
| NCT05470465 | Phase 1 | Sep 1, 2022 | Food and Drug Administration, Leiden University, Spaulding Clinical Research Inc. |
| NCT05353543 | N/A | May 1, 2022 | Hangzhou First People Hospital, Zhejiang University |
Organizations
Research & Development (222)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 46 | 32 | 5 | 1998 |
| National Institute of Mental Health (NIMH) | Government | 18 | 3 | 4 | 1998 |
| Department of Veteran Affairs | Government | 15 | 11 | 4 | 1996 |
| Pfizer | For profit | 10 | 9 | 4 | 2003 |
| Harvard University | Academic/Hospital | 9 | 7 | 4 | 1998 |
| Columbia University | Academic/Hospital | 8 | 6 | 4 | 1999 |
| Capital Medical University | Academic/Hospital | 6 | 5 | 3 | 2011 |
| Duke University | Academic/Hospital | 6 | 5 | 2 | 2002 |
| Emory University | Academic/Hospital | 6 | 3 | 3 | 2003 |
| Sungkyunkwan University | Academic/Hospital | 6 | 6 | 2 | 1999 |
| University of Pittsburgh | Academic/Hospital | 6 | 4 | 3 | 1998 |
| Otsuka | For profit | 5 | 5 | 2 | 2009 |
| AstraZeneca | For profit | 4 | 3 | 2 | 2005 |
| Mylan | For profit | 4 | 4 | 1 | 2005 |
| Noven Therapeutics | For profit | 4 | 4 | 3 | 2008 |
| PRACS | For profit | 4 | 0 | 1 | 2005 |
| Sanofi | For profit | 4 | 4 | 2 | 2003 |
| Zhejiang University | Academic/Hospital | 4 | 4 | 1 | 2022 |
| Eli Lilly | For profit | 3 | 3 | 3 | 2004 |
| Forest Laboratories | For profit | 3 | 2 | 3 | 2011 |
Marketing (37)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Jun 20, 2017 |
| Alembic | For profit | MKTG | Sep 24, 2025 |
| Allergan PLC (2015) | For profit | MKTG | Jun 20, 2017 |
| Ani Pharmaceuticals | For profit | MKTG | Sep 3, 2021 |
| Annora Pharma | For profit | MKTG | Mar 5, 2026 |
| Apotex | For profit | NDA2 | Dec 29, 1992 |
| Apotex | For profit | MKTG | Jul 30, 2003 |
| Apotex | For profit | SYN | Dec 4, 2006 |
| Apotex | For profit | NDA | Dec 29, 1992 |
| Aurobindo Pharma | For profit | MKTG | Jul 25, 2007 |
| Aurobindo Pharma | For profit | SYN | Jun 29, 2007 |
| Boehringer Ingelheim | For profit | MKTG | Jun 29, 2007 |
| Cadila Healthcare | For profit | MKTG | Aug 27, 2021 |
| Chartwell Pharmaceuticals | For profit | MKTG | Aug 15, 2005 |
| Epic Pharma Llc | For profit | MKTG | Aug 11, 2021 |
| Jubilant Innovation Ltd. | For profit | MKTG | Nov 27, 2015 |
| LEGACY PHARMA | For profit | MKTG | Jun 28, 2013 |
| Lannett Company, Inc. | For profit | MKTG | Jun 10, 2016 |
| Lupin | For profit | MKTG | Jan 20, 2017 |
| Lupin | For profit | SYN | Jan 20, 2017 |
| Mylan | For profit | SYN | Jun 29, 2007 |
| Mylan | For profit | MKTG | Mar 8, 2004 |
| Novitium Pharma | For profit | MKTG | Sep 3, 2021 |
| Oxford Pharmaceuticals | For profit | MKTG | Jun 21, 2010 |
| PHARMOBEDIENT | For profit | MKTG | Mar 8, 2004 |
| Prinston Inc | For profit | MKTG | Oct 31, 2014 |
| Roxane Laboratories | For profit | MKTG | Jun 29, 2007 |
| Sciecure Pharma Inc | For profit | MKTG | Jun 12, 2018 |
| Sebela Pharmaceuticals | For profit | NDA2 | Jul 3, 2003 |
| Shijiazhuang Pharma Group (CSPC) | For profit | MKTG | Feb 16, 2021 |
| Sinotherapeutics | For profit | MKTG | Aug 11, 2021 |
| Sun Pharmaceuticals | For profit | MKTG | Jun 29, 2007 |
| Teva | For profit | SYN | Aug 15, 2005 |
| Teva | For profit | MKTG | Jun 29, 2007 |
| Upsher-Smith Laboratories | For profit | MKTG | Mar 8, 2004 |
| Yiling Pharmaceutical Inc. | For profit | MKTG | Nov 2, 2021 |
| Zydus Discovery DMCC | For profit | MKTG | Mar 7, 2007 |